P/E ratio for Enanta Pharmaceuticals (ENTA)
P/E ratio as of April 2024 (TTM): -1.98
According to Enanta Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.97781. At the end of 2022 the company had a P/E ratio of -7.99.
P/E ratio history for Enanta Pharmaceuticals from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.99 | -46.77% |
| 2021 | -15.0 | 2.72% |
| 2020 | -14.6 | -140.7% |
| 2019 | 35.9 | 125.66% |
| 2018 | 15.9 | -51.18% |
| 2017 | 32.6 | -148.66% |
| 2016 | -67.0 | -781.77% |
| 2015 | 9.83 | -14.77% |
| 2014 | 11.5 | -229.34% |
| 2013 | -8.92 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -627.03% | 🇺🇸 USA |
 Novartis NVS | 26.5 | -1,439.19% | 🇨🇭 Switzerland |
 AbbVie ABBV | 45.5 | -2,398.06% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | 30.4 | -1,636.14% | 🇺🇸 USA |
 Merck MRK | 71.8 | -3,728.15% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -669.29% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.